This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
Perioperative Durvalumab for Resectable Non-Small Cell Lung Cancer
This paper looked at the immunotherapy agent Durvalumab used in the perioperative period for resectable NSCLC. A total of 802 patients were enrolled in the study, of which 400 received Durvalumab and the remaining 402 a placebo. The two primary endpoints measured were event-free survival and pathological complete resection. Perioperative Durvalumab plus neoadjuvant chemotherapy, as compared with neoadjuvant chemotherapy alone, was significantly associated with improved results in the two primary endpoints measured. Event-free survival was longer with Durvalumab. The stratified hazard ratio for disease progression, recurrence, or death was 0.68 (p=0.004.) At twelve months, event-free survival was observed with 73.4 percent of Durvalumab patients compared to 64.5 percent of placebo patients. The incidence of pathological complete response was significantly greater with Durvalumab then with placebo (17.2 percent and 4.3 percent respectively, p <0.001). Moreover, a benefit was seen regardless of PD-L1 expression and stage.